Literature DB >> 28252961

Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.

Ewgenij Proschak1, Pascal Heitel1, Lena Kalinowsky1, Daniel Merk1.   

Abstract

Fatty acids beyond their role as an endogenous energy source and storage are increasingly considered as signaling molecules regulating various physiological effects in metabolism and inflammation. Accordingly, the molecular targets involved in formation and physiological activities of fatty acids hold significant therapeutic potential. A number of these fatty acid targets are addressed by some of the oldest and most widely used drugs such as cyclooxygenase inhibiting NSAIDs, whereas others remain unexploited. Compounds orthosterically binding to proteins that endogenously bind fatty acids are considered as fatty acid mimetics. On the basis of their structural resemblance, fatty acid mimetics constitute a family of bioactive compounds showing specific binding thermodynamics and following similar pharmacokinetic mechanisms. This perspective systematically evaluates targets for fatty acid mimetics, investigates their common structural characteristics, and highlights demands in their discovery and design. In summary, fatty acid mimetics share particularly favorable characteristics justifying the conclusion that their therapeutic potential vastly outweighs the challenges in their design.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28252961     DOI: 10.1021/acs.jmedchem.6b01287

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning.

Authors:  Daniel Merk; Francesca Grisoni; Kay Schaller; Lukas Friedrich; Gisbert Schneider
Journal:  ChemistryOpen       Date:  2018-10-02       Impact factor: 2.911

2.  Scaffold hopping from synthetic RXR modulators by virtual screening and de novo design.

Authors:  Daniel Merk; Francesca Grisoni; Lukas Friedrich; Elena Gelzinyte; Gisbert Schneider
Journal:  Medchemcomm       Date:  2018-06-06       Impact factor: 3.597

3.  A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Authors:  Md Abdul Hye Khan; Jurema Schmidt; Anna Stavniichuk; John D Imig; Daniel Merk
Journal:  Biochem Pharmacol       Date:  2019-05-23       Impact factor: 5.858

4.  Nuclear Receptor Chemical Reporter Enables Domain-Specific Analysis of Ligands in Mammalian Cells.

Authors:  Taku Tsukidate; Qiang Li; Howard C Hang
Journal:  ACS Chem Biol       Date:  2020-09-10       Impact factor: 5.100

Review 5.  Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.

Authors:  Ganesh V Halade; Laurence M Black; Mahendra Kumar Verma
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

6.  A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis.

Authors:  Yong-Hyun Han; Kyong-Oh Shin; Ju-Yeon Kim; Daulat B Khadka; Hyeon-Ji Kim; Yong-Moon Lee; Won-Jea Cho; Ji-Young Cha; Bong-Jin Lee; Mi-Ock Lee
Journal:  J Clin Invest       Date:  2019-03-11       Impact factor: 14.808

7.  An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.

Authors:  Leslie E Lupien; Evan M Dunkley; Margaret J Maloy; Ian B Lehner; Maxwell G Foisey; Maddison E Ouellette; Lionel D Lewis; Darcy Bates Pooler; William B Kinlaw; Paul W Baures
Journal:  J Pharmacol Exp Ther       Date:  2019-07-12       Impact factor: 4.030

Review 8.  Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing.

Authors:  José J M Vitória; Diogo Trigo; Odete A B da Cruz E Silva
Journal:  Cell Mol Life Sci       Date:  2022-01-28       Impact factor: 9.261

9.  Multi-Target Drugs for Kidney Diseases.

Authors:  John D Imig; Daniel Merk; Eugen Proschak
Journal:  Kidney360       Date:  2021-08-02

Review 10.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.